[Rhabdomyolysis caused by pravastatin and type 1 macrocreatine kinase].
The authors report a case of rhabdomyolysis which occurred in a 61 year old woman who was receiving pravastatin and who was also found to present with type 1 macrocreatine kinase. Drug induced rhabdomyolysis is common, particularly with HMG Coenzyme A reductase inhibitors. The authors describe the onset of an adverse effect of this type with pravastatin, a recently marketed drug, as has been previously described for lovastatin and simvastatin. The concomitant detection of macrocreatine kinase, the incidence of which is estimated to be between 2 and 5% in the population, raises the question of whether rhabdomyolysis of this type may occur preferentially in patients with this biological anomaly.
Decoulx
E
E
Service de Cardiologie C, Hôpital Cardiologique, Centre Hospitalier Régional Universitaire, Lille.
Millaire
A
A
de Groote
P
P
Mahieux
G
G
Ducloux
G
G
D003402:Creatine Kinase / Q000032:analysis* / Q000502:physiology; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D008875:Middle Aged; D017035:Pravastatin / Q000009:adverse effects*; D012206:Rhabdomyolysis / Q000139:chemically induced*
D003402:Creatine Kinase; D017035:Pravastatin
Rhabdomyolyse sous pravastatine et macrocréatine kinase de type 1.